Effectiveness of LORlatinib as a Real-World, first-line treatment in ALK-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients in Italy(LOR-ALK).

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS1000000856
• Study ID:
  1000000856
• Official title and acronym:
  Effectiveness of LORlatinib as a Real-World, first-line treatment in ALK-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients in Italy(LOR-ALK).
• DARWIN EU® study:
  No
• Study countries:
  Italy
• Study description:
  This is an observational, non-interventional, prospective, multicenter, and international wide study with the category of a PASS, which primary endpoint will describe the effectiveness of Lorlatinib as real-world PFS, assessed by the physician.
• Study status:
  Planned

Research institutions and networks

Institutions

Pfizer

Study timelines

Date when funding contract was signed

Planned:24/12/2025

Study start date

Planned:28/02/2026

Date of final study report

Planned:30/09/2030

Sources of funding

Pharmaceutical company and other private sector 

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable